+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor VIII"

From
From
From
From
From
From
From
From
From
From
From
Acquired Hemophilia Treatment Market Report 2025 - Product Thumbnail Image

Acquired Hemophilia Treatment Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Hemophilia Market Report 2025 - Product Thumbnail Image

Hemophilia Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Coagulation Factor Deficiency Global Market Report 2025 - Product Thumbnail Image

Coagulation Factor Deficiency Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Hemophilia Drugs - Global Strategic Business Report - Product Thumbnail Image

Hemophilia Drugs - Global Strategic Business Report

  • Report
  • June 2025
  • 182 Pages
  • Global
From
From
Rare Hemophilia Factors - Global Strategic Business Report - Product Thumbnail Image

Rare Hemophilia Factors - Global Strategic Business Report

  • Report
  • June 2025
  • 93 Pages
  • Global
From
From
From
Loading Indicator

The Factor VIII market is a segment of the hematological drugs market, which includes drugs used to treat blood-related disorders. Factor VIII is a protein that helps blood to clot, and is used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Factor VIII is typically administered intravenously, and is available in both recombinant and plasma-derived forms. The Factor VIII market is highly competitive, with a number of companies offering products. These include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Additionally, there are several smaller companies that offer Factor VIII products, such as Octapharma, Kedrion, and Biotest. Show Less Read more